Brief: Nasdaq Approves Landos Biopharma's Application To Transfer To Nasdaq Capital Market
16/12/2022 14:59
Dec 16 (Reuters) - Landos Biopharma Inc LABP.O :
* LANDOS BIOPHARMA- ON DEC 13, NASDAQ APPROVED CO'S
APPLICATION TO
TRANSFER TO NASDAQ CAPITAL MARKET, EFFECTIVE AT OPENING OF
BUSINESS ON DEC 15, 2022
* LANDOS BIOPHARMA INC- NASDAQ GRANTED CO AN ADDITIONAL
180-CALENDAR DAY COMPLIANCE PERIOD, TO REGAIN COMPLIANCE WITH
THE MINIMUM BID PRICE REQUIREMENT
Source text: (https://bit.ly/3WlNefY)
Further company coverage: LABP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Landos Biopharma
See all newsLandos Biopharma Inc expected to post a loss of 100 cents a share - Earnings Preview
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Super Micro, Micron Technology, Navios Maritime
U.S. STOCKS ON THE MOVE-Landos Biopharma, Foot Locker, US energy sector
Brief: AbbVie To Acquire Landos Biopharma